Gencor Pacific is eyeing new product development opportunities aimed at improving the quality of life in individuals who experience the lingering effects of COVID-19 infection, following new trial findings on one of its trademarked ingredients.
An ingredient commonly isolated from soybeans, peanuts, and egg yolks, has been shown in a recent review to act in similar pathways as cannabidiol (CBD), with researchers highlighting that it was a safer and legally recognised alternative.
Gencor is venturing into the hair care oral supplement and topical application category, with an RCT studying the benefits of ageratum conyzoides oral supplementation and topical application to take place this year.